Pharmaceutical Companies

Lyme disease is transmitted primarily through the bites of infected ticks.

OmniAb was spun out of Ligand Pharmaceuticals in 2022 and has since built a broad network of pharmaceutical partnerships.

If approved and launched, the vaccine will complement CanSinoBIO’s recently approved three-component DTaP vaccine, Tripecia® (DT3cP Infant), expanding the company’s pertussis-containing vaccine portfolio across age groups.

The initiative aims to help patients with the greatest medical needs access modern therapies within a coordinated framework that complements the UAE’s national health insurance system.

The latest approval expands the clinical use of ivonescimab in China and follows previous NMPA authorisations for regimens containing the molecule.

The FDA approval was supported by findings from the Phase 3a ONWARDS clinical program, which evaluated once-weekly Awiqli® in adults with type 2 diabetes.

The transaction will be completed through a share purchase agreement with SEVER Life Sciences, under which Alfasigma will acquire 100% of Nordic Group and its subsidiaries.

The U.S. National Cancer Institute estimates that more than 500 rare cancers exist, many of which receive limited public attention despite their significant impact on patients and families.

The investment forms part of BMS’ broader US$ 40 billion commitment to strengthening its US operations, including its manufacturing and research and development (R&D) capabilities.

As part of the transaction, Actio Biosciences will establish a new privately held company dedicated to developing treatments for genetic rare neurological diseases.